Physician documentation tips
Cartilage Biopsy (Stage 1)
Since authorization is dependent upon the documentation recorded at the biopsy harvest, and insurance company case managers often rely on measurable objective data, it is important to include the following information collected at the biopsy harvest in the patient's operative report:
- Prior treatments and current symptoms (unless noted in H&P)
- Number of defects
- Defect location(s)
- Defect size (after debridement)
- Grade of defect(s)
- Health and stability of rest of the knee
- Absence of Osteoarthritis (CARTICEL is not indicated for use in patients with OA)
- Clearly state medical necessity for and intent to treat with CARTICEL.
- Clearly state that the patient was educated about CARTICEL as a treatment option
- If the patient has worker’s compensation, establish causation and indicate how correcting the defect will impact return to work status
- Use the word “implant” not “transplant”
Post-operative visit notes:
- Clearly state the intent to treat the patient with ACI
CARTICEL Implantation (Stage 2)
Modifiers:
The CPT Code alone is not sufficient to describe the details of a surgical procedure, providers may wish to provide additional information in the claims submission. The AMA has developed Modifiers which are designed to allow providers to more precisely communicate the extent of the professional services performed. Some modifiers that may be used in conjunction with 27412 include:
22: Unusual Procedural Services - When the service(s) provided is greater than that usually required for the listed procedure, it may be identified by adding modifier “22” to the usual procedure number. A report may also be appropriate.
Example: This modifier may be used to describe procedure when multiple (more than one) or large uncontained defects are being treated.
51: Multiple Procedures - When multiple procedures, other than Evaluation and Management Services, are performed at the same session by the same provider, the primary procedure or service may be reported as listed. The additional procedure(s) or service(s) may be identified by appending modifier “51” to the additional procedure or service code(s). Note: This modifier should not be appended to designated “add-on” codes.
Example: This modifier may be used to describe a condition when multiple procedures are performed to treat a co-existing condition or morbidity concurrent to the implantation, i.e. Meniscal allograft reconstruction; proximal tibial or distal femoral osteotomy or tibial tubercle osteotomy.
*Note: All CPT codes, above, are taken from AMA CPT, 2005, Introduction. CPT codes, descriptions, and material only are copyright 2004 American Medical Association. All rights reserved. No fee schedules, basic units, relative values, or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.
Indications and Usage
Carticel® (autologous cultured chondrocytes) is an autologous cellular product indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft).
CARTICEL should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown.
CARTICEL is not indicated for the treatment of cartilage damage associated with generalized osteoarthritis.
CARTICEL is not recommended for patients with total meniscectomy unless surgically reconstructed prior to or concurrent with CARTICEL implantation.
Important Safety Information
CARTICEL should not be used in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides or materials of bovine origin.
It should not be used in patients who have previously had cancer in the bones, cartilage, fat or muscle of the treated limb.
Pre-existing conditions, including meniscal tears, joint instability, or malalignment should be assessed and treated prior to or concurrent with CARTICEL implantation.
CARTICEL is not routinely tested for transmissible infectious diseases and may transmit disease to the healthcare provider handling CARTICEL.
Use of CARTICEL in children, patients over age 65, or in joints other than the knee has not yet been assessed.
The occurrence of subsequent surgical procedures (SSPs), primarily arthroscopy, following CARTICEL implantation is common. In the Study of the Treatment of Articular Repair (STAR), forty-nine percent (49%) of patients underwent an SSP on the treated knee, irrespective of their relationship to CARTICEL, during the 4-year follow up. The most common serious adverse events (≥5% of patients), derived from STAR, include arthrofibrosis/joint adhesions, graft overgrowth, chondromalacia or chondrosis, cartilage injury, graft complication, meniscal lesion, graft delamination, and osteoarthritis.
For more information on CARTICEL, please see the Package Insert (PDF).